1-4 of 4
Geraldine Ferron-Brady, PhD
Close
Sort by
Journal Articles

DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) Vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Suzanne Trudel, MD, Randy Davis, PhD, Nicole M. Lewis, MSc, Kalpana K. Bakshi, MSc, Bikramjit Chopra, PhD, Rocio Montes de Oca, PhD, Geraldine Ferron-Brady, PhD, Laurie Eliason, MPH, Brandon E. Kremer, MD PhD, Ira Gupta, MD, Frank S. Wu, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 4.
https://doi.org/10.1182/blood-2020-139785
Published: 2020
Journal Articles

Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Paul G. Richardson, MD, Ajay Nooka, MDMPH, Hang Quach, MDFRACP,FRCPA,MBBS, Suzanne Trudel, MD, David Routledge, Kevin Song, MD, Hareth Nahi, MD, Sofia Paul, Josephine Khan, Maria Brouch, Geraldine Ferron-Brady, PhD, Anne Yeakey, MD, Chris Shelton, Rocio Montes de Oca, PhD, L. Mary Smith, Ellie Im, Christoph M Ahlers, Elaine M Paul, Beata Holkova, Ira Gupta, MD, Brandon E. Kremer, MD PhD, Paula Rodriguez-Otero, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 1–2.
https://doi.org/10.1182/blood-2020-139182
Published: 2020
Journal Articles

DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)

Rakesh Popat, Ajay Nooka, MDMPH, Keith Stockerl-Goldstein, MD, Rafat Abonour, MD, Ryan Ramaekers, MD, Amit Khot, MD, Adam Forbes, MD, Cindy Lee, MD, Bradley Augustson, MBBS FRACP FRCPA, Andrew Spencer, Maria-Victoria Mateos, MD PhD, Bikramjit Chopra, PhD, Rachel Rogers, MS, Deborah A Smith, PharmD, Jacqueline Davidge, PhD, Rocio Montes de Oca, PhD, Geraldine Ferron-Brady, PhD, Anne Yeakey, MD, Mala Talekar, MD, Brandon E. Kremer, MD PhD, Ira Gupta, MD, Hang Quach, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–20.
https://doi.org/10.1182/blood-2020-139332
Published: 2020
Journal Articles

Exposure-Response (E-R) for Ocular Safety Endpoints for Belantamab Mafodotin (Belamaf), a B-Cell Maturation Antigen (BCMA)-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study

Geraldine Ferron-Brady, PhD, Chetan Rathi, PhD, Jon Collins, PhD, Herbert Struemper, PhD, Joanna Opalinska, MD, Roxanne C Jewell, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 20–21.
https://doi.org/10.1182/blood-2020-139698
Published: 2020